Effects of rituximab combined with CHOP chemotherapy on serum TK-1 and VEGF levels in patients with non-Hodgkin's lymphoma
10.3969/j.issn.1673-4130.2018.05.024
- VernacularTitle:利妥昔单抗配合CHOP化疗对非霍奇金淋巴瘤患者血清TK-1、VEGF的影响
- Author:
Lei SHEN
1
;
Yili ZHANG
;
Jianjun BIAN
;
Lei FU
Author Information
1. 蚌埠医学院第二附属医院
- Keywords:
non-Hodgkin's lymphoma;
CHOP chemotherapy;
rituximab;
thymidine kinase 1;
vascular endothelial growth factor
- From:
International Journal of Laboratory Medicine
2018;39(5):602-605
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effects of rituximab combined with CHOP chemotherapy on serum Thymidine kinase 1 (TK-1) and vascular endothelial growth factor (VEGF) in patients with non-Hodgkin lymphoma,and to provide guidance for clinical research.Methods A total of 24 patients with non-Hodgkin's lymphoma treated in our hospital from January 2013 to March 2016 were randomly divided into the control group and the observation group,and each with 12 cases.All patients were examined before and after treatment,the control group was only treated with CHOP chemotherapy,and the observation group was treated with rituximab combined with CHOP chemotherapy.The patients were followed up within 1-2 years after treatment.The therapeutic effects of all patients were observed,the TK-1 and VEGF levels were measured and the incidence rate of adverse reactions was recorded.Results The efficiency rates of patients in the observation group and the control group were 66.67％ and 50.00％,respectively after treatment,and the observation group was significantly better than the control group,the difference was statistically significant (P＜0.05);the TK-1 and VEGF levels of the two groups were significantly decreased after treatment (P＜0.05),there was a statistically significant difference.But the two indexes of observation group was significantly lower than the control group,the difference was significant (P＜0.05);the control group showed 1 case of liver dysfunc tion after treatment,4 cases of gastrointestinal dysfunction,1 case of decreased white blood cells,while the observation group were 1,3 and 1 case,respectively.There were no significant differences between two groups (P＞0.05).Conclusion With the treatment of rituximab combined with CHOP chemotherapy,serum TK-1 and VEGF levels of patients with non-Hodgkin lymphoma decreased significantly,the poor prognosis has been significantly improved,and this treatment is worth popularizing in clinical application.
